WaveMan
WaveMan · Company
AARD · Aardvark Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

AARD Aardvark Therapeutics (AARD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001774857
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
36
13F, latest reported quarter

What the filings say about AARD

Insiders, 180 days
-$395.0K net sold
1 seller · 100% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$380.7K
2 notices

Aardvark Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Aardvark Therapeutics, Inc. insiders sold a net $395.0K of stock across 14 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Sun Nelson
See Remarks
SELL
2026-09-11 SEC
62,000
$321.2K
-80.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on Sep 10, 2026.
  • -31.7% median (-7.9% mean) 90-day return after 3 previous buys.
  • The trade is 174.8% of the 35,475 shares held after it.
  • No other insider sold within 30 days.
  • 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sun Nelson sold about $321.2K of AARD under a 10b5-1 plan on Sep 11, 2026, the largest insider sale at the company on our record; 36 funds added in the latest 13F quarter.
Sun Nelson
See Remarks
SELL
2026-09-11 SECtraded 2026-09-10
14,754
$73.8K
-80.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 11, 2025.
  • -31.7% median (-7.9% mean) 90-day return after 3 previous buys.
  • The trade is 15.1% of the 97,475 shares held after it.
  • No other insider sold within 30 days.
  • 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Sun Nelson sold about $73.8K of AARD under a 10b5-1 plan on Sep 10, 2026, the largest insider sale at the company on our record; 36 funds added in the latest 13F quarter.
Sun Nelson
Chief Financial Officer
BUY
2025-12-12 SECtraded 2025-12-11
3,000
$43.2K
-92.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 9, 2025.
  • +21.5% median (+21.5% mean) 90-day return after 2 previous buys.
  • The trade is 2.8% of the 108,484 shares held after it.
  • 1 other insider bought within 30 days.
  • 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sun Nelson bought about $43.2K of AARD on Dec 11, 2025; 1 other insider bought within 30 days and 36 funds added in the latest 13F quarter.
Lee Tien-Li
Chief Executive Officer
BUY
2025-12-12 SECtraded 2025-12-11
7,000
$101.4K
-92.5%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Sep 15, 2025.
  • +71.1% median (+49.2% mean) 90-day return after 5 previous buys.
  • The trade is 0.5% of the 1,551,613 shares held after it.
  • 1 other insider bought within 30 days.
  • 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lee Tien-Li bought about $101.4K of AARD on Dec 11, 2025; 1 other insider bought within 30 days and 36 funds added in the latest 13F quarter.
Lee Tien-Li
Chief Executive Officer
BUY
2025-09-16 SECtraded 2025-09-15
6,500
$61.8K
-90.2%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Sep 12, 2025.
  • +75.3% median (+50.2% mean) 90-day return after 4 previous buys.
  • The trade is 0.4% of the 1,539,884 shares held after it.
  • 1 other insider bought within 30 days.
  • 36 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lee Tien-Li bought about $61.8K of AARD on Sep 15, 2025; 1 other insider bought within 30 days and 36 funds added in the latest 13F quarter.
14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 9 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$395.0K over 180 days
-$395.0K over 90 days
below 54% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
36 funds bought in last quarter
below 59% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.3% of the float short (float per yahoo 2026-10-26) · 5.3 days to cover · settled 2026-09-30
below 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch AARD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-90.2%12M
-90%-45%-1%+44%2025-102025-122026-022026-042026-062026-082026-10 2026-09-11 · Sun Nelson sold $321.2K2025-12-11 · Lee Tien-Li bought $101.4K2026-09-10 · Sun Nelson sold $73.8K2025-12-11 · Sun Nelson bought $43.2K2026-09-11 · NELSON SUN filed to sell $169.9K2026-09-10 · NELSON SUN filed to sell $210.8K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns AARD: institutional holders (13F)

13F holdings, latest reported quarter
Decheng Capital LLC
3,917,299 sh
$22.6M
CITADEL ADVISORS LLC
1,283,166 sh
$7.4M
Laurion Capital Management LP
1,034,459 sh
$6.0M
VANGUARD CAPITAL MANAGEMENT LLC
562,877 sh
$3.2M
AQR CAPITAL MANAGEMENT LLC
480,249 sh
$2.8M

Congress trades in AARD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

AARD planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
NELSON SUN
Filed 2026-09-11
$169.9K
NELSON SUN
Filed 2026-09-10
$210.8K

AARD mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$138.2K position · as of 2026-06-30
0.1%
ALPS Medical Breakthroughs ETF
$92.2K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$245.5K position · as of 2026-06-30
0.0%
Invesco Nasdaq Biotechnology ETF
$4.7K position · as of 2026-05-31
0.0%
1290 VT Micro Cap Portfolio
$15.4K position · as of 2026-06-30
0.0%
VIP Disciplined Small Cap Portfolio
$46.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 2
0 active
2
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $395.0K sold by insiders over 180 days, 36 funds added last quarter, $380.7K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

AARD financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$0
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$69.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-66.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-61.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-69.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-294.1%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Revenue$0n/a
Operating income-$62.7M-$22.8M
Net income-$57.6M-$20.6M
EPS (diluted)-2.93-5.15
Operating cash flow-$54.2M-$18.1M
Cash$47.1M$61.6M
SEC XBRL, fiscal years, as known on 2026-10-27

AARD Stock Sonar score 4/7 axes

Find similar shapesCompare

AARD ranks highest on risk and compliance (58th percentile) and institutional and government (41st), and lowest on insider conviction (1st), among Pharma & Biotech peers.

Profitability
40
Inputs
  • Return on equity-66.0% · 44 pct, sector of 545
  • Return on assets-61.1% · 38 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-69.7% · 36 pct, sector of 576
Insider conviction
0
Inputs
  • Net Form 4 buying (codes P and S), 180dno Form 4 purchase or sale (code P or S) in 180 days
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
41
Inputs
  • Funds adding, latest quarter36 · 41 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
58
Inputs
  • Short interest, % of float+4.3% · 62 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+9.8% · 55 pct, sector of 511
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

AARD filings, in plain words

Are Aardvark Therapeutics insiders buying or selling AARD?

In the 180 days to 2026-10-27, Aardvark Therapeutics insiders were net sellers, a net $395.0K across purchases and sales reported on Form 4, by 1 seller.

Are there planned insider sales of AARD?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $380.7K of stock; the latest, by NELSON SUN, was filed 2026-09-11.

Read the full summary

In the 180 days to 2026-10-27, Aardvark Therapeutics insiders were net sellers of AARD, a net $395.0K across purchases and sales reported on Form 4 by 1 seller. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $380.7K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies